u/Odd-Doctor8453

我对公司管理层对管线进度的把控极度失望

CHRS 关于 “Mid-2026 临床数据读出” 的官方证据链：
① 2026年1月13日****｜J.P. Morgan Healthcare Conference
时间：2026/01/13，10:30 AM PST
地点：San Francisco, California
会议：44th Annual J.P. Morgan Healthcare Conference
演讲人：Coherus Chairman & CEO Denny Lanfear
CHRS 当天正式 Corporate Presentation 明确给出：
Tagmokitug + Toripalimab｜2L HNSCC：Mid 2026
Tagmokitug + Toripalimab｜GC/GEJ/EAC：Mid 2026
Casdozokitug + Toripalimab + Bevacizumab｜1L HCC：Mid 2026
Tagmokitug｜CRC：H2 2026
Tagmokitug｜ESCC：H2 2026
同一天，公司将该 Investor Presentation 作为正式材料提交 SEC（8-K / Exhibit 99.1）。
SEC Accession No.：0001104659-26-003117
这证明至少从 2026年1月13日开始，公司正式公开给出的** HNSCC**、GI 和 HCC 数据时间就是 Mid-2026。

② 2026年3月9**日｜**FY2025/Q4 Earnings Update
时间：2026/03/09
公司继续表示 2026 年将迎来：
“multiple 2026 clinical readouts”
这一阶段没有撤回此前 JPM 给出的 Mid-2026 数据时间表。

③ 2026年5月11**日｜Q1 2026 Earnings Call
时间：2026/05/11，5:00 PM EDT
这是整个时间线中非常关键的一次表态。
此时距离“年中”已经很近，但公司仍没有下调时间预期。
针对 Casdozokitug 一线 HCC 数据，CMO Rosh Dias 明确表示：
“We are tracking to initial data around mid-year.”
同时，公司确认该 HCC Phase 2 randomized trial 已经：
“Patient accrual complete”
即患者入组已经完成。
管理层同时表示：
“We are on target for multiple data readouts as planned in 2026.”
也就是说，截至2026年5月11**日，公司仍明确预期 HCC initial data 在 mid-year 左右出现。

④** 后续时间发生变化
原始时间表：
Mid-2026 / around mid-year
即大致对应：
2026年6月至7月附近**
后来公司将成熟数据公开窗口调整至：
October 2026 / early October 2026
因此，从公开 guidance 的变化来看：
2026/01/13：Mid-2026
↓
2026/03/09：继续维持2026多个数据读出
↓
2026/05/11：仍明确表示 around mid-year / on target
↓
之后：调整至 October / early October 2026
公司最初明确计划 HNSCC**、GI 和 HCC 的部分数据在 Mid-2026 读出，并且直到2026年5月11日，管理层仍然维持接近 mid-year 的预期。
如果最终数据在 early October 才公开，相对于原来的 mid-year guidance，时间大约向后移动了 2–3个月**。
如果是疗效不足、数据不稳定导致等待更多患者或更长随访，这是负面信号！

几年前，我因为持有surf而过度到了chrs，chrs收购surf的时候也发了cvr，看样子又是一样的剧本

为什么，为什么

说实话，已经不报任何期望，前面多转空就是实际表现。前面本来平仓了的，今晚又空了， 说实话我衷心希望chrs成功。

对于chrs这种高风险标的来说，当前确实是煎熬，持有50万股chrs，这是我们目前最大的一笔高风险投资。鉴于当前情况大概率十月份前跌入一块以下。如果十月数据不理想目标价位0.5。大概率到时候可以退市了

CHRS did not suddenly lose $62 million because R&D or SG&A exploded. Core operating expenses actually declined. Most of the unusually large Q2 cash outflow appears related to settling legacy TSA and other accrued liabilities from the biosimilar divestitures.
The quarter was operationally better than the headline cash decline suggests. However, liquidity risk is now very real, and the investment thesis increasingly depends on October clinical data, continued LOQTORZI growth, and whether management can secure non-dilutive funding before another major equity raise.
1. LOQTORZI continues to grow
Q2 LOQTORZI net revenue was approximately $13.6 million:
Up about 15% sequentially from $11.8 million in Q1
Up approximately 37% year over year
Total Q2 revenue was approximately $14.3 million
This is a respectable commercial trend for a rare-cancer indication. LOQTORZI is clearly not a failed launch.
The problem is scale: $13.6 million of quarterly product revenue is still far below the level required to support CHRS’s current R&D and commercial infrastructure.
LOQTORZI provides a commercial foundation and a proprietary PD-1 backbone, but it cannot yet finance the company by itself.
2. Operating expenses did not increase
The headline cash decline may make it look as though spending suddenly accelerated. The income statement says otherwise.
Approximate Q2 operating expenses:
R&D: $21.4 million, essentially flat sequentially and down from about $26.3 million last year
SG&A: $21.0 million, down from $23.1 million in Q1 and approximately $26.0 million last year
Total costs and expenses: approximately $46.6 million, down from about $48.5 million in Q1
Continuing-operations net loss improved to roughly $33.3 million, versus approximately $44.9 million a year ago
So the company is reducing headcount and infrastructure costs while continuing to fund casdozokitug and tagmokitug.
The operating organization is becoming leaner, not more bloated.
3. Why did cash fall from $167 million to $105.3 million?
Q2 operating cash flow was approximately negative $62.1 million, but this was not entirely current-quarter operating expense.
A major component appears to be the settlement of liabilities already recognized from the divested biosimilar operations.
TSA-related payables and accrued liabilities declined from:
$61.6 million at the end of Q1
To approximately $22.7 million at the end of Q2
That is a reduction of roughly $39 million in one quarter.
Accrued rebates, fees, and reserves also declined materially. These payments consume cash when settled, but they do not appear as an equivalent new R&D or SG&A expense in Q2 because much of the expense was recognized previously.
Q1 also looked less damaging because CHRS raised approximately $53.6 million through its February equity offering. That financing almost fully offset Q1 operating cash burn.
Q2 had no comparable financing inflow, so the cash decline was fully visible.
4. The good news: much of the legacy cash burden may now be behind the company
Remaining TSA-related liabilities are now approximately $22.7 million, substantially lower than the $61.6 million balance at the end of Q1.
This suggests future quarterly operating cash flow should improve relative to Q2, assuming:
No new major one-time obligations
Core operating expenses remain near current levels
LOQTORZI revenue continues growing
Clinical trial spending does not accelerate sharply
Q2 should therefore not be mechanically annualized as a $248 million yearly cash burn.
However, even after removing legacy settlements, the company still appears to have a normalized quarterly operating deficit in the neighborhood of $25–35 million.
That remains the central financial risk.
5. Cash runway is now the major issue
CHRS ended Q2 with approximately $105.3 million in cash, equivalents, and marketable securities.
If one also considers the remaining $22.7 million of TSA-related liabilities, the freely available financial cushion is meaningfully smaller than the headline cash number, although the timing and accounting treatment of those obligations matter.
A rough estimate suggests CHRS may have around 2.5 to 3.5 quarters of practical runway without:
Licensing revenue
Milestone payments
Additional equity financing
A strategic transaction
Much stronger LOQTORZI sales
This is not immediate bankruptcy territory, but it is also not a comfortable balance sheet.
Investors should assume financing risk remains high unless October data meaningfully improves CHRS’s negotiating position.
6. Casdozokitug: the timeline slipped, but the thesis is not dead
Management previously guided the randomized first-line HCC Phase 2 readout to mid-2026. It now expects initial data in the second half of 2026, with sufficiently mature datasets expected to be publicly discussed around early October.
That is a delay and should be counted against management’s execution and communication credibility.
However, a delayed oncology readout does not automatically mean failure. Possible explanations include:
More time needed for evaluable responses
Additional confirmation scans
More mature duration-of-response data
PFS follow-up
Safety review
Biomarker and subgroup analysis
The key question is whether casdozokitug adds a meaningful benefit over the randomized toripalimab plus bevacizumab control.
The previous single-arm data — approximately 38% ORR and 17% complete responses — were encouraging, but the randomized study is the real test. Historical comparisons can be misleading.
For October, investors need to see:
Number of evaluable patients in each arm
Confirmed ORR
Complete response rate
Duration of response
PFS trend
Discontinuation rates
Incremental toxicity
Whether the benefit is consistent across doses and patient subgroups
If management only presents biomarker changes without clear clinical separation, the market will probably view the result as weak.
7. Tagmokitug: “emerging clinical activity” is encouraging, but incomplete
Management stated that tagmokitug plus toripalimab in HNSCC is showing emerging evidence of clinical activity and that this increased confidence in the CCR8/Treg-depletion mechanism.
That is directionally positive. Management would be taking reputational and legal risk by using that language if there were no activity at all.
But investors still do not know:
Number of treated and evaluable patients
Number of responses
Confirmed ORR
Duration of response
Prior PD-1 exposure
Dose level
Safety profile
Whether activity exceeds what toripalimab alone could produce
CCR8 competitors have shown that strong intratumoral Treg depletion does not necessarily translate into strong clinical response rates.
Tagmokitug therefore remains a high-upside but early and unproven asset.
8. The quarter is both better and worse than it initially appears
Positives
LOQTORZI revenue grew sequentially and year over year
R&D and SG&A were controlled
Net loss improved
Legacy TSA liabilities declined substantially
Casdozokitug remains active in randomized Phase 2
Management is signaling clinical activity for tagmokitug
Early October now provides a more concrete catalyst window
The company still owns global rights to both main clinical assets
Negatives
The original mid-2026 data timeline was not met
Cash fell to $105.3 million
Normalized operations still burn significant cash
LOQTORZI remains too small to fund the company
Existing financing capacity creates dilution risk
Supply collaborations with J&J, Zumutor, and others have not yet produced meaningful upfront cash
“Emerging activity” is not a substitute for patient-level data
Management’s history of option repricing and dilution reduces investor trust
9. My overall assessment
Q2 was operationally better but financially more urgent.
The company is not suffering from runaway operating expenses. It is working through legacy liabilities while maintaining roughly stable R&D investment and reducing SG&A.
But the balance sheet is now approaching the point where management needs one of the following:
Strong October clinical data
An ex-U.S. licensing transaction with meaningful upfront cash
A strategic partnership or milestone payment
A substantial acceleration in LOQTORZI revenue
Another equity raise
The most likely bear case is not immediate Chapter 11. It is:
moderate clinical data, no major licensing deal, and another dilutive financing at a weak share price.
The bull case is:
clear randomized HCC separation and/or credible tagmokitug activity, followed by a licensing transaction that funds development without heavily diluting shareholders.
Bottom line
CHRS remains a high-risk, high-upside clinical catalyst investment, not a conventional value stock.
Q2 did not prove that the business model is sustainable, but it also did not show that management has lost operating control.
The next major valuation event is the October dataset. Until then, the debate is simple:
Are the assets strong enough to attract non-dilutive capital?
Or will shareholders have to fund another year of development through dilution?
That question matters far more than the headline $62 million Q2 cash outflow.
Not financial advice. I am evaluating CHRS as a speculative biotech position where clinical and financing outcomes can produce extreme volatility.

已经拿chrs四五年了。社区🈶长期持有者吗？你们当前兜什么看法。是否🈶相关行业经验的专业人士给解读下当前chrs管线的处境